These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36604259)

  • 1. Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer.
    Adachi M; Nakayama M; Matsumoto S; Shima Y; Uemaetomari I; Yoshimura T; Onishi K; Senarita M; Tabuchi K
    Auris Nasus Larynx; 2023 Aug; 50(4):601-606. PubMed ID: 36604259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of posttreatment neutrophil-lymphocyte ratio in head and neck squamous cell carcinoma treated by chemoradiotherapy.
    Kim DY; Kim IS; Park SG; Kim H; Choi YJ; Seol YM
    Auris Nasus Larynx; 2017 Apr; 44(2):199-204. PubMed ID: 27269133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
    Gao Y; Liu D
    Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck.
    Kimura H; Hamauchi S; Kawai S; Onozawa Y; Yasui H; Yamashita A; Ogawa H; Onoe T; Kamijo T; Iida Y; Onitsuka T; Yokota T
    Int J Clin Oncol; 2020 Feb; 25(2):258-266. PubMed ID: 31620932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the pretreatment geriatric nutritional risk index for predicting severe adverse events in patients with head and neck cancer treated with chemoradiotherapy.
    Nakayama M; Ohnishi K; Adachi M; Ii R; Matsumoto S; Nakamura M; Miyamoto H; Hirose Y; Nishimura B; Tanaka S; Wada T; Tabuchi K
    Auris Nasus Larynx; 2022 Apr; 49(2):279-285. PubMed ID: 34509306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
    Kusaka T; Shiga K; Katagiri K; Saito D; Oikawa SI; Ikeda A; Tsuchida K; Miyaguchi J; Ohashi YU; Ariga H; Tanno K
    Anticancer Res; 2022 Dec; 42(12):6047-6056. PubMed ID: 36456163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
    Komatsu M; Shiono O; Taguchi T; Sakuma Y; Nishimura G; Sano D; Sakuma N; Yabuki K; Arai Y; Takahashi M; Isitoya J; Oridate N
    Jpn J Clin Oncol; 2014 May; 44(5):416-21. PubMed ID: 24688084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
    Hitt R; Iglesias L; López-Pousa A; Berrocal-Jaime A; Grau JJ; García-Girón C; Martínez-Trufero J; Guix M; Lambea-Sorrosal J; Del Barco-Morillo E; León-Vintró X; Cunquero-Tomas AJ; Baste N; Ocaña A; Cruz-Hernández JJ;
    Clin Transl Oncol; 2021 Apr; 23(4):764-772. PubMed ID: 32797376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer.
    Lu HJ; Yang CC; Wang LW; Chu PY; Tai SK; Chen MH; Yang MH; Chang PM
    Biomed Res Int; 2015; 2015():307576. PubMed ID: 25793192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
    Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
    BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
    Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF
    Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein level predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.
    Zeng YC; Xue M; Chi F; Xu ZG; Fan GL; Wu R; Fan YC; Zhong WZ; Wang SL; Zhang XY; Wu LN; Chen XD; Jin XY; Duan QY; Xu R; Chen W; Qian HC; Xiao YP
    Tumour Biol; 2012 Jun; 33(3):891-5. PubMed ID: 22311704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Iocca O; Farcomeni A; Di Rocco A; Di Maio P; Golusinski P; Pardiñas López S; Savo A; Pellini R; Spriano G
    Oral Oncol; 2018 May; 80():40-51. PubMed ID: 29706187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemoradiotherapy with capecitabine/cisplatin versus 5-fluorouracil/cisplatin in resectable laryngohypopharyngeal squamous cell carcinoma.
    Ahn D; Sohn JH; Kim JH; Lee JE; Park SH; Kim JC
    Ear Nose Throat J; 2016 Feb; 95(2):E34-42. PubMed ID: 26930342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nutritional surveillance in head and neck cancer patients during radiotherapy--the difference between concurrent chemoradiotherapy using high-dose cisplatin and radiotherapy alone].
    Nakahara S; Yoshino K; Fujii T; Uemura H; Suzuki M; Nishiyama K; Inohara H
    Nihon Jibiinkoka Gakkai Kaiho; 2012 Oct; 115(10):902-9. PubMed ID: 23214048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
    Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
    Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
    Hitt R; Grau JJ; López-Pousa A; Berrocal A; García-Girón C; Irigoyen A; Sastre J; Martínez-Trufero J; Brandariz Castelo JA; Verger E; Cruz-Hernández JJ;
    Ann Oncol; 2014 Jan; 25(1):216-25. PubMed ID: 24256848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study.
    Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R
    Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
    Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
    Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.